The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

Abstract Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear which PARPi is optimal in mCRPC patients with HRD in...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Qiyu Zhu, Junru Chen, Haoyang Liu, Jinge Zhao, Chenhao Xu, Guangxi Sun, Hao Zeng
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2024-06-01
Cyfres:	BMC Cancer
Pynciau:	Poly (ADP- ribose) polymerase inhibitors Homologous recombination deficiency Metastatic castration-resistance prostate cancer Progression-free survival Adverse events
Mynediad Ar-lein:	https://doi.org/10.1186/s12885-024-12388-2
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!